| Literature DB >> 11594571 |
A H Rook1, M H Zaki, M Wysocka, G S Wood, M Duvic, L C Showe, F Foss, M Shapiro, T M Kuzel, E A Olsen, E C Vonderheid, R Laliberte, M L Sherman.
Abstract
Recent phase I and phase II trials using recombinant human interleukin-12 (rhIL-12) for cutaneous T cell lymphoma (CTCL) have been completed. Observations on 32 evaluable patients revealed an overall response rate approaching 50 percent. Biopsy of regressing lesions revealed an increase in numbers of CD8+ and/or TIA-1+ T cells. These results suggest that rhIL-12 may induce lesion regression by augmenting antitumor cytotoxic T cell responses. Future trials will be focused on strategies for further immune enhancement by the concomitant use of additional immune augmenting cytokines with rhIL-12.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11594571 DOI： 10.1111/j.1749-6632.2001.tb03721.x
Source DB: PubMed Journal: Ann N Y Acad Sci ISSN： 0077-8923 Impact factor: 5.691